Last reviewed · How we verify

Low-dose intravenous tenecteplase — Competitive Intelligence Brief

Low-dose intravenous tenecteplase (Low-dose intravenous tenecteplase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Tissue plasminogen activator (tPA). Area: Cardiovascular.

phase 3 Fibrinolytic agent / Tissue plasminogen activator (tPA) Plasminogen / Fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Low-dose intravenous tenecteplase (Low-dose intravenous tenecteplase) — The George Institute. Tenecteplase is a fibrinolytic agent that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Low-dose intravenous tenecteplase TARGET Low-dose intravenous tenecteplase The George Institute phase 3 Fibrinolytic agent / Tissue plasminogen activator (tPA) Plasminogen / Fibrin
Fibrinolytic once daily Fibrinolytic once daily University of North Carolina, Chapel Hill marketed Fibrinolytic agent / Thrombolytic Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis low-dose tenecteplase intravenous thrombolysis Southwest Hospital, China marketed Fibrinolytic agent / Tissue plasminogen activator (tPA) Plasminogen / Fibrin
Fibrinolytic twice daily Fibrinolytic twice daily University of North Carolina, Chapel Hill marketed Fibrinolytic agent Plasminogen / Fibrin
Intravenous thrombolysis agents Intravenous thrombolysis agents Second Affiliated Hospital, School of Medicine, Zhejiang University phase 3 Thrombolytic agent / Fibrinolytic agent Plasminogen / Fibrin
Intravenous rhTNK-tPA Intravenous rhTNK-tPA Xinqiao Hospital of Chongqing phase 3 Thrombolytic agent / Fibrinolytic Plasminogen / Fibrin
Recombinant human tissue plasminogen activator Recombinant human tissue plasminogen activator Angde Biotech Pharmaceutical Co., Ltd. phase 3 Fibrinolytic agent / Thrombolytic Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Tissue plasminogen activator (tPA) class)

  1. Central Hospital, Nancy, France · 1 drug in this class
  2. Genentech, Inc. · 1 drug in this class
  3. Hospital Clinic of Barcelona · 1 drug in this class
  4. NHS Greater Glasgow and Clyde · 1 drug in this class
  5. Southwest Hospital, China · 1 drug in this class
  6. The George Institute · 1 drug in this class
  7. University of Manitoba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose intravenous tenecteplase — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-intravenous-tenecteplase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: